Aim: To assess whether reasons for hepatitis C virus (HCV) therapy non-initiation differentially affect racial and ethnic minorities with human immunodeficiency virus (HIV)/HCV co-infection.
Methods: Analysis included co-infected HCV treatment-naïve patients in the University of North Carolina CFAR HIV Clinical Cohort (January 1, 2004 and December 31, 2011). Medical records were abstracted to document non-modifiable medical (e.g., hepatic decompensation, advanced immunosuppression), potentially modifiable medical (e.g., substance abuse, severe depression, psychiatric illness), and non-medical (e.g., personal, social, and economic factors) reasons for non-initiation. Statistical differences in the prevalence of reasons for non-treatment between racial/ethnic groups were assessed using the two-tailed Fisher's exact test. Three separate regression models were fit for each reason category. Odds ratios and their 95%CIs (Wald's) were computed.
Results: One hundred and seventy-one patients with HIV/HCV co-infection within the cohort met study inclusion. The study sample was racially and ethnically diverse; most patients were African-American (74%), followed by Caucasian (19%), and Hispanic/other (7%). The median age was 46 years (interquartile range = 39-50) and most patients were male (74%). Among the 171 patients, reasons for non-treatment were common among all patients, regardless of race/ethnicity (50% with ≥ 1 non-modifiable medical reason, 66% with ≥ 1 potentially modifiable medical reason, and 66% with ≥ 1 non-medical reason). There were no significant differences by race/ethnicity. Compared to Caucasians, African-Americans did not have increased odds of non-modifiable [adjusted odds ratio (aOR) = 1.47, 95%CI: 0.57-3.80], potentially modifiable (aOR = 0.72, 95%CI: 0.25-2.09) or non-medical (aOR = 0.90, 95%CI: 0.32-2.52) reasons for non-initiation.
Conclusion: Race/ethnicity alone is not predictive of reasons for HCV therapy non-initiation. Targeted interventions are needed to improve access to therapy for all co-infected patients, including minorities.
Keywords: Antiviral therapy; Co-infection; Hepatitis C virus; Human immunodeficiency virus; Race.
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection.Hepatology. 2013 Jan;57(1):249-57. doi: 10.1002/hep.25800. Hepatology. 2013. PMID: 22532055
Lower liver-related death in African-American women with human immunodeficiency virus/hepatitis C virus coinfection, compared to Caucasian and Hispanic women.Hepatology. 2012 Nov;56(5):1699-705. doi: 10.1002/hep.25859. Epub 2012 Aug 27. Hepatology. 2012. PMID: 22618868 Free PMC article. Clinical Trial.
Racial/ethnic differences in spontaneous HCV clearance in HIV infected and uninfected women.Dig Dis Sci. 2013 May;58(5):1341-8. doi: 10.1007/s10620-012-2486-8. Epub 2012 Nov 24. Dig Dis Sci. 2013. PMID: 23179159 Free PMC article. Clinical Trial.
Human Leukocyte Antigen-E Alleles are Associated with Hepatitis C Virus, Torque Teno Virus, and Toxoplasma Co-infections but are not Associated with Hepatitis B Virus, Hepatitis D Virus, and GB Virus C Co-infections in Human Immunodeficiency Virus Patients.J Glob Infect Dis. 2016 Apr-Jun;8(2):75-81. doi: 10.4103/0974-777X.182121. J Glob Infect Dis. 2016. PMID: 27293362 Free PMC article.
Correlates of spontaneous clearance of hepatitis C virus in a Danish human immunodeficiency virus type 1 cohort.Scand J Infect Dis. 2011 Oct;43(10):798-803. doi: 10.3109/00365548.2011.589077. Epub 2011 Jul 5. Scand J Infect Dis. 2011. PMID: 21728744